Evidence map›Paper›PMID 37676377›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2024

ATM-Mediated translocation of RanBPM regulates DNA damage response by stabilizing p21 in non-small cell lung cancer cells.

Tanggang Deng, Lin Xie, Chen Xiaofang, Zhenbin Zhang, Yugang Xiao, Yuchong Peng, Linglong Yin, Yongming Fu, Xiong Li

Open access · hybridAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tanggang Deng *Center for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China. dengtanggang@163.com.
Lin Xie *Center for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Chen XiaofangCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Zhenbin ZhangCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Yugang XiaoCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Yuchong PengCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Linglong YinCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Yongming FuCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China.
Xiong LiCenter for Clinical Precision Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, China. lixiong@gdpu.edu.cn.
First Affiliated Hospital of Guangdong Pharmaceutical University · CNGuangdong Pharmaceutical University · CN

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515011053Guangzhou Science and Technology Plan Project 202102020153the National Natural Science Foundation of China NSFC 82103422
6 · The paper itself

Abstract

purposePlatinum-based chemotherapy remains a standard-of-care for most patients with advanced non-small cell lung cancer (NSCLC). DNA damage response (DDR) induced by platinum or Etoposide activated a panel of cell cycle-regulatory proteins including p21 through p53 pathway. Previous studies have reported that RanBPM has been involved in various cellular processes such as DDR by interacting with multiple proteins. However, the underlying mechanism remains unclear.

methodsNSCLC tissue microarrays were used for assessing the expression of RanBPM by immunohistochemical staining. The roles of RanBPM in the DDR of NSCLC progression was examined in in vitro cell lines and in vivo animal models. The regulation of RanBPM on protein stability and ubiquitination levels were investigated by immunoblots and in vivo ubiquitylation assay.

resultsThe level of p21 or RanBPM is lower in NSCLC than non-malignant tissues and has a highly positive correlation. Mechanistically, RanBPM protein physically interacts with p21, and RanBPM deubiquitinates p21 by recruiting a deubiquitinase USP11 to maintain protein stability of p21. RanBPM silencing significantly decreased p21 protein level. Conversely, RanBPM overexpression led to the accumulation of endogenous p21 protein regardless of p53 status. Functionally, RanBPM regulates DDR in a p21-dependent manner. Furthermore, DNA damage significantly promoted the nuclear translocation of RanBPM protein through ATM signaling pathways.

conclusionRanBPM is a novel regulator of P21 protein stability, and plays a critical role in the regulation of DDR.

Indexed as

Adaptor Proteins, Signal TransducingAtaxia Telangiectasia Mutated ProteinsCarcinoma, Non-Small-Cell LungCyclin-Dependent Kinase Inhibitor p21Cytoskeletal ProteinsLung NeoplasmsNuclear ProteinsAnimalsDNA DamageDNA RepairHumansThiolester HydrolasesTumor Suppressor Protein p53Adaptor Proteins, Signal TransducingAtaxia Telangiectasia Mutated ProteinsATM protein, humanCyclin-Dependent Kinase Inhibitor p21Cytoskeletal ProteinsNuclear ProteinsRan binding protein 9Thiolester HydrolasesTumor Suppressor Protein p53USP11 protein, humanDeubiquitinationDNA damagep21RanBPMUSP11

Identifiers

PMID37676377
PMCPMC10899406
OpenAlexW4386497948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.